Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
Frank McCormick, a director of BridgeBio Pharma, Inc. (BBIO), reported transactions dated 09/05/2025. On that date he exercised a stock option to acquire 74,000 shares at an exercise price of $11.92 per share. He also sold 74,000 shares with a weighted average sale price of $53.156 per share (range $52.96–$53.39). After the reported transactions the Form 4 shows 83,275 shares owned directly, 879,979 shares owned indirectly by the Francis P. McCormick Rev Trust, and 84,814 shares underlying options held directly.
BridgeBio Pharma director and CEO Neil Kumar reported planned sales under a Rule 10b5-1 plan adopted March 31, 2025. The Form 4 discloses multiple dispositions on September 4–5, 2025 totaling 223,090 shares sold of BridgeBio common stock at weighted-average prices in several ranges between about $50.52 and $53.91 per share. Following the reported transactions, the filing shows Kumar's indirect beneficial holdings via two trusts of 4,678,447 shares and 875,686 shares, respectively. The report was signed by an attorney-in-fact and states the reporting person disclaims beneficial ownership except for any pecuniary interest.
BridgeBio Pharma, Inc. (BBIO) Form 144 notice shows a proposed sale of 74,000 common shares through Morgan Stanley Smith Barney on 09/05/2025 for an aggregate market value of $3,932,056.60. The filing reports 191,168,504 shares outstanding and lists the exchange as NASDAQ. The shares to be sold were acquired on 09/05/2025 by stock option exercise from the issuer and paid for in cash.
The filing also discloses a prior sale by Frank P. McCormick of 100,000 common shares on 06/24/2025 producing gross proceeds of $4,422,800.00. The filer certifies they are unaware of undisclosed material adverse information about the issuer.
Thomas Trimarchi, President and Chief Financial Officer of BridgeBio Pharma, Inc. (BBIO), reported a sale of 42,237 shares of common stock on 08/21/2025 at a weighted-average price of $49.4846 per share (sales ranged from $49.08 to $49.77). After the transaction he beneficially owned 421,081 shares, reported as a direct holding. The Form 4 discloses the transaction code as a sale and includes an explanatory footnote that the reporting person can provide a breakdown of shares sold at each price within the stated range.
BridgeBio Pharma, Inc. (BBIO) director and CEO Neil Kumar reported insider sales under a Rule 10b5-1 plan. On 08/20/2025 the reporting person sold a total of 26,156 shares in two transactions (25,728 and 428 shares) at weighted average prices shown in the filing. Following those sales the filing reports 223,518 and 223,090 shares beneficially owned in the two reported lines, held directly. The report also discloses indirect holdings of 4,718,447 shares via the Kumar Haldea Revocable Trust and 915,686 shares via the Kumar Haldea Family Irrevocable Trust, of which the reporting person is a co-trustee. The transactions were effected pursuant to a 10b5-1 sales plan adopted March 31, 2025. The Form 4 was signed by an attorney-in-fact on 08/22/2025.
BridgeBio Pharma, Inc. (BBIO) Form 144 notice: An affiliate proposes to sell 42,237 shares of common stock through Morgan Stanley Smith Barney LLC on 08/21/2025, with an aggregate market value of $2,090,076.83. The filing lists total outstanding shares of 191,168,504. The securities to be sold were acquired as restricted stock on multiple dates (08/16/2024; 11/16/2024; 02/16/2025; 05/16/2025; 08/16/2025) in amounts shown in the filing.
The filing also discloses sales by Thomas Trimarchi on 08/18/2025 totaling 17,353 shares for gross proceeds of $871,722.75. The notice contains the seller's certification that no undisclosed material adverse information is known to the signer.
BridgeBio Pharma (BBIO) filed a Form 144 notifying a proposed sale of 26,156 common shares acquired as restricted stock units on 08/16/2025. The filing lists Morgan Stanley Smith Barney LLC as the broker and shows an aggregate market value of $1,279,289.96 for the proposed sale, with the shares to be sold on 08/20/2025 on NASDAQ. The securities to be sold were granted and acquired from the issuer on 08/16/2025 and paid on that date, identified as Restricted Stock Units. The filing also reports multiple prior Rule 10b5-1 sales during July and August 2025, each for 20,000 shares executed by related trusts, totaling eight reported transactions.
BridgeBio Pharma insider filing: Maricel Apuli, the company's Chief Accounting Officer, reported a transaction dated 08/16/2025 related to the vesting of restricted stock units. The filing shows 4,781 shares of common stock were withheld to satisfy tax obligations at a reported price of $51.32 per share following the vesting of 9,409 RSUs.
After the withholding, Ms. Apuli beneficially owns 137,078 shares of BridgeBio Pharma (BBIO) on a direct basis. The Form 4 is a routine disclosure of compensation-related share withholding and does not include derivative transactions or other purchases or sales.
BridgeBio Pharma insider filing: Thomas Trimarchi, the company’s President and Chief Financial Officer, reported transactions in the issuer’s common stock. On 08/16/2025, 21,317 shares were withheld to satisfy tax withholding related to the vesting of 38,547 restricted stock units, leaving the reporting person with 480,671 shares beneficially owned. On 08/18/2025, Trimarchi sold a total of 17,353 shares under a Rule 10b5-1 sales plan adopted March 31, 2025, at weighted average prices of $50.1437 and $50.9439, reducing beneficial ownership to 463,318 shares. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
BridgeBio Pharma director and CEO Neil Kumar reported transactions on 08/16/2025 showing vesting and tax-withholding activity tied to Restricted Stock Units (RSUs). A total of 64,697 RSU shares vested (reported as acquisition), and 32,855 shares were withheld to satisfy tax obligations at an indicated price of $51.32 per share. After these transactions the reporting person directly beneficially owned 282,101 shares and indirectly beneficially owned 4,718,447 and 915,686 shares through two trusts, of which he is co-trustee. Multiple tranches of RSUs continue to vest quarterly with no expiration.